About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT01514500

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

This trial is conducted in Europe. The aim of this trial is to assess safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the invest...

Lead sponsor: Novo Nordisk A/S•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

Novo Nordisk A/S

Age

20 - 45 years

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•Healthy, non-smoking male subjects
•BMI (body mass index) between 18.0 and 28.0 kg/m\^2, both incl.
•Body weight 50 to 100 kg, both incl.

Exclusion Criteria

•Strenuous exercise within 4 days prior to dosing
•Receipt of any investigational medicinal product within 3 months prior to randomisation

Related studies

Enrolling By Invitation

Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed

NCT06109935 · Growth Hormone Deficiency in Children

Active Not Recruiting

Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®

NCT05230550 · Adult Growth Hormone Deficiency

COMPLETEDPhase 3

A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.

NCT04970654 · Growth Hormone Deficiency in Children

Not Yet RecruitingPhase 2

A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)

NCT07259564 · Adult Growth Hormone Deficiency (AGHD)

TERMINATEDPhase 3

A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency

NCT01909479 · Adult Growth Hormone Deficiency

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 24, 2020Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment105

Start dateJan 2012

Last updatedDec 24, 2020

Condition

Growth Hormone Disorder Adult Growth Hormone Deficiency Growth Hormone Deficiency in Children Healthy

Locations shown

Novo Nordisk Investigational Site

Neuss

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 24, 2020Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions